Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022 2022-12-02 08:30
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab 2022-10-13 09:00
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China 2022-09-06 15:20
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China 2022-09-02 19:00
Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China 2022-09-02 17:14
Jacobio Pharma Announces 2022 Interim Results 2022-08-24 00:32
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting 2022-05-28 00:22
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83% 2022-03-22 22:50
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China 2022-02-24 10:32
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China 2021-12-06 09:16
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy 2021-08-31 22:05
Jacobio Pharmaceuticals Announces 2021 Interim Results 2021-08-31 22:01
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor 2021-08-03 09:00
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment 2021-06-18 08:31
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor 2021-05-03 09:30
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results 2021-03-29 13:11
1 2